A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) (NCT06937229)
A Phase 3, Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-3)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the long-term efficacy and safety of combined formulation of xanomeline tartrate/trospium chloride in an immediate release (IR) capsule (KarXT) and xanomeline enteric capsules (KarX-EC) in participants with agitation associated with Alzheimer's Disease who completed the parent studies CN012-0023 or CN012-0024.
Who can join: Review the eligibility criteria below.
Location: Local Institution - 2609 — Chandler, Arizona
Age range: 55 Years to 90 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (256 Sites)
Showing the first 25 of 256 sites.
- Local Institution - 2609 — Chandler, Arizona
- Imaging Endpoints — Scottsdale, Arizona
- Local Institution - 1657 — Anaheim, California
- Local Institution - 1637 — La Jolla, California
- Local Institution - 2625 — Long Beach, California
- Local Institution - 2642 — Long Beach, California
- Local Institution - 2649 — Orange, California
- Local Institution - 2613 — Pasadena, California
- Local Institution - 1662 — Pomona, California
- Local Institution - 1639 — Torrance, California
- Local Institution - 1651 — Walnut Creek, California
- Local Institution - 2602 — Bonita Springs, Florida
- Local Institution - 2626 — Hialeah, Florida
- Local Institution - 1618 — Miami, Florida
- Nuovida Research Center — Miami, Florida
- Local Institution - 1635 — Orlando, Florida
- Progressive Medical Research — Port Orange, Florida
- IPTB Clinical Research — Tampa, Florida
- Hope Research Network - Miami — Virginia Gardens, Florida
- Local Institution - 2611 — Atlanta, Georgia
- Local Institution - 1636 — Gaithersburg, Maryland
- Boston Center for Memory — Newton, Massachusetts
- Local Institution - 2615 — Worcester, Massachusetts
- Local Institution - 2618 — Ann Arbor, Michigan
- Local Institution - 1620 — Troy, Michigan
📞 Contact the Study Coordinator
Phone: (855) 907-3286
Email: Clinical.Trials@bms.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Alzheimer Disease
- The Use of Memantine for Prevention of Alzheimer's Disease — Charlottesville, Virginia
- Investigation of Inflammation Using [C-11]-CS1P1 — St Louis, Missouri
- Sleep Disturbance and Emotion Regulation Brain Dysfunction as Mechanisms of Neuropsychiatric Symptoms in Alzheimer's Dementia — Palo Alto, California
- A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study) — Gilbert, Arizona
- High Frequency Light and Sound Stimulation to Improve Brain Functions in Alzheimer's Disease — Cambridge, Massachusetts
- A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease — Phoenix, Arizona
Explore by condition: All Alzheimer Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.